Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-10 01:35 | 2026-03-05 | GRAL | GRAIL, Inc. | RAGUSA ROBERT P | Director, Officer; Chief Executive Officer | Services-Medical Laboratories | SALE | $48.48 | 8,441 | $409,246 | 642,084 | -1.3% |
| 2026-03-04 04:15 | 2026-03-02 | GRAL | GRAIL, Inc. | RAGUSA ROBERT P | Director, Officer; Chief Executive Officer | Services-Medical Laboratories | SALE | $50.17 | 37,504 | $1,881,418 | 650,525 | -5.5% |
| 2025-12-06 00:12 | 2025-12-03 | GRAL | GRAIL, Inc. | RAGUSA ROBERT P | Director, Officer; Chief Executive Officer | Services-Medical Laboratories | SALE | $95.24 | 40,000 | $3,809,536 | 688,029 | -5.5% |
| 2025-10-17 01:18 | 2025-10-15 | GRAL | GRAIL, Inc. | RAGUSA ROBERT P | Director, Officer; Chief Executive Officer | Services-Medical Laboratories | SALE | $68.88 | 7,239 | $498,622 | 727,388 | -1.0% |
| 2025-05-06 03:44 | 2025-05-02 | GRAL | GRAIL, Inc. | RAGUSA ROBERT P | Director, Officer; Chief Executive Officer | Services-Medical Laboratories | SALE | $33.93 | 94,035 | $3,190,608 | 734,627 | -11.3% |
| 2025-04-03 23:43 | 2025-03-11 | GRAL | GRAIL, Inc. | RAGUSA ROBERT P | Director, Officer; Chief Executive Officer | Services-Medical Laboratories | SALE | $31.21 | 7,625 | $237,976 | 828,662 | -0.9% |
| 2025-03-12 23:07 | 2025-03-07 | GRAL | GRAIL, Inc. | RAGUSA ROBERT P | Director, Officer; Chief Executive Officer | Services-Medical Laboratories | SALE | $31.21 | 7,625 | $237,976 | 828,662 | -0.9% |
| 2025-03-07 00:27 | 2025-03-05 | GRAL | GRAIL, Inc. | RAGUSA ROBERT P | Director, Officer; Chief Executive Officer | Services-Medical Laboratories | SALE | $41.51 | 994 | $41,261 | 836,287 | -0.1% |
| 2024-10-18 01:32 | 2024-10-15 | GRAL | GRAIL, Inc. | RAGUSA ROBERT P | Officer; Chief Executive Officer | Services-Medical Laboratories | SALE | $14.02 | 123,454 | $1,730,825 | 612,661 | -16.8% |
| 2021-03-06 00:50 | 2021-03-03 | TWST | Twist Bioscience Corp | RAGUSA ROBERT P | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $133.05 | 10,588 | $1,408,745 | 1,898 | -84.8% |
| 2020-12-03 01:34 | 2020-11-30 | ILMN | ILLUMINA, INC. | RAGUSA ROBERT P | Officer; SVP, Global Quality & Ops | Laboratory Analytical Instruments | SALE | $314.82 | 2,890 | $909,827 | 4,092 | -41.4% |
| 2020-09-03 02:29 | 2020-08-31 | ILMN | ILLUMINA, INC. | RAGUSA ROBERT P | Officer; SVP, Global Quality & Ops | Laboratory Analytical Instruments | SALE | $355.18 | 5,000 | $1,775,907 | 8,103 | -38.2% |
| 2020-06-17 23:15 | 2020-06-15 | ILMN | ILLUMINA, INC. | RAGUSA ROBERT P | Officer; SVP, Global Quality & Ops | Laboratory Analytical Instruments | SALE | $340.76 | 5,000 | $1,703,810 | 13,056 | -27.7% |
| 2020-02-06 01:37 | 2020-02-03 | ILMN | ILLUMINA, INC. | RAGUSA ROBERT P | Officer; SVP, Global Quality & Ops | Laboratory Analytical Instruments | SALE | $293.10 | 1,253 | $367,254 | 7,888 | -13.7% |
| 2019-11-06 00:18 | 2019-11-01 | ILMN | ILLUMINA, INC. | RAGUSA ROBERT P | Officer; SVP, Global Quality & Ops | Laboratory Analytical Instruments | SALE | $297.28 | 1,674 | $497,647 | 10,192 | -14.1% |
| 2019-08-13 00:22 | 2019-08-08 | ILMN | ILLUMINA, INC. | RAGUSA ROBERT P | Officer; SVP, Global Quality & Ops | Laboratory Analytical Instruments | SALE | $293.09 | 2,230 | $653,591 | 11,866 | -15.8% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.